As the community re-gathers, be there with your peers to lay out priorities, changes and challenges that the IPF community now faces in a world with COVID-19
- Networking: Network one-to-one with KOLS, drug sponsors and service providers prioritizing IPF and anti-fibrotic drug development. Discuss face-to-face how their expertise and innovations could transform your candidate’s success and help to dramatically impact patient lives
- Drug Development Specific Insights: Get first-hand knowledge on how the latest scientific discoveries could be applied to target identification, translational success, fibrosis quantification and more, giving you innovative foresight to close the IPF translational gap and overcome poor clinical attrition
- Share your data: Present your work to peers and thought leaders to gain critical and candid feedback. Establish pivotal new partnerships and meaningful connections specific to your program and its results
From establishing consensus around trial endpoints to the practicalities and potential of IPF concepts in wider fibrosis, we will unite preclinical, clinical and therapeutic strategy professionals under one roof for another successful edition of the IPF Summit.